Clinical trials: Emergency Department Visits
- Condition Emergency Department Visits
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies
This was a retrospective cross-sectional database study using administrative data (study period: 1/1/2003 through 7/31/2008). Managed care enrollees (aged >40 years) having at least one Hospitalization with primary or secondary…
- Trial name
- NCT01332461
- Testing
- fluticasone propionate/salmeterol xinafoate combination, Other maintenance Treatments (OMT)
- Volunteers
- 5,677 people
- Sponsor
- GlaxoSmithKline
Influenza
Study on the Burden of Influenza-related Hospitalizations and Emergency Room (ER) Visits in Children in Spain
This study aims to quantify the inpatient and ER visits burden of laboratory-confirmed influenza, and compare the clinical features, severity, complications, risk factors and socioeconomic impact of influenza in children…
- Trial name
- NCT01592799
- Testing
- Throat swab and/or nasopharyngeal swab, Data collection
- Where
- Spain
- Volunteers
- 501 people
- Sponsor
- GlaxoSmithKline
Asthma
Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit
The objective of this study is to compare readmission to the emergency department for asthma in asthma patients who receive treatment with fluticasone propionate and salmeterol oral inhaler after an initial emergency department…
- Trial name
- NCT01332357
- Testing
- Fluticasone propionate/salmeterol combination ED MD, Fluticasone propionate/salmeterol combination OP MD
- Volunteers
- 6,139 people
- Sponsor
- GlaxoSmithKline
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation